Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3201561 | 0.92 | SCN9A (0.47) | SCN9APOLBSMN1; SMN2MEN1GAA | |
| SCHEMBL3196894 | 0.88 | SCN9A (0.44) | SCN9APOLBSMN1; SMN2MEN1GAA | |
| SCHEMBL3214632 | 0.85 | SCN9A (0.46) | SCN9ASMN1; SMN2MEN1GAAKMT2A | |
| SCHEMBL3204885 | 0.82 | MRGPRX4 (0.43) | POLBSMN1; SMN2MEN1GAAKMT2A | |
| SCHEMBL4453207 | 0.82 | SCN9A (0.43) | SCN9APOLBSMN1; SMN2MEN1GAA | |
| SCHEMBL3210207 | 0.81 | CYP19A1 (0.63) | SCN9APOLBSMN1; SMN2 | |
| SCHEMBL3203639 | 0.80 | MEP1B (0.46) | MEP1B | |
| SCHEMBL3212416 | 0.79 | SLC2A1 (0.46) | MEN1KMT2AMAPK1 | |
| SCHEMBL4448923 | 0.78 | S1PR5 (0.42) | POLBSMN1; SMN2MEN1KMT2ABRD4 | |
| SCHEMBL3204784 | 0.78 | CYP19A1 (0.44) | SMN1; SMN2MEN1GAAKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-9309179-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA (FR) | 2016-04-12 | — | — | US | disclosed |
| US-9309179-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA (FR) | 2016-04-12 | — | — | US | disclosed |
| US-9309179-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA (FR) | 2016-04-12 | — | — | US | disclosed |
| US-20140213589-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA S.A.S. (FR) | 2014-07-31 | — | — | US | disclosed |
| US-8722746-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA S.A.S. (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722746-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA S.A.S. (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722746-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA S.A.S. (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | FAB PHARMA (FR) | 2010-02-18 | — | — | US | disclosed |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | FAB PHARMA (FR) | 2010-02-18 | — | — | US | disclosed |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | FAB PHARMA (FR) | 2010-02-18 | — | — | US | disclosed |
| EP-2010495-A2 | NEW HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | Mutabilis SA (FR) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007135562-A2 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS S.A. (FR) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135562-A2 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS S.A. (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213589-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | HPD, HPGDS, EPX | SCN9A 3870/4885POLB 1149/4885SMN1; SMN2 4582/4885 |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | HPD, HPGDS, EPX | SCN9A 3870/4885POLB 1149/4885SMN1; SMN2 4582/4885 |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | HPD, HPGDS, EPX | SCN9A 3870/4885POLB 1149/4885SMN1; SMN2 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.